Clinical Trial Update: Real-World Effectiveness and Pharmacogenetics of Belzutifan in VHL Syndrome: The BELIEVE-VHL Trial [Phase 2]

View source ↗

Summary

Phase 2 BELIEVE-VHL trial is assessing real-world effectiveness and pharmacogenetics of belzutifan in Von Hippel-Lindau syndrome; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Endolymphatic Sac Tumor
• Hemangioblastoma
• Pancreatic Neuroendocrine Tumor
• Paraganglioma
• Pheochromocytoma
• Retinal Angiomatous Proliferation
• Von Hippel-lindau Disease

Drugs mentioned

• Welireg (belzutifan)

Snippet

Sponsor: José Claudio Casali da Rocha | Conditions: Von Hippel Lindau, Von Hippel Lindau Disease | Phase 2 | Status: RECRUITING